| Product Dating |
| McKesson Acceptable Dating: we will ship >= 30 days | McKesson Acceptable Dating: we will ship >= 30 days | McKesson Acceptable Dating: we will ship >= 30 days | McKesson Acceptable Dating: we will ship >= 30 days |
| Features and Benefits |
|
- FLUCELVAX QUADRIVALENT is an inactivated vaccine indicated for active immunization for the prevention of influenza disease caused by influenza virus subtypes A and type B contained in the vaccine
- FLUCELVAX QUADRIVALENT is approved for use in persons 6 Months of age and older
- FLUCELVAX QUADRIVALENT 5 mL multi-dose vial formulation contains no antibiotics
- FLUCELVAX QUADRIVALENT is standardized according to United States Public Health Service requirements for the 2021 - 2022 influenza season and is formulated to contain a total of 60 micrograms (mcg) hemagglutinin (HA) per 0.5 mL dose in the recommended ratio of 15 mcg HA of each of the following four influenza strains:
- A/Idaho/07/2018 (an A/Brisbane/02/2018 (H1N1)pdm09-like virus), A/Indiana/08/2018 (an A/Kansas/14/2017 (H3N2)-like virus), B/Iowa/06/2017 (a B/Colorado/06/2017-like virus), B/Singapore/INFTT-16-0610/2016 (a B/Phuket/3073/2013-like virus)
|
- FLUCELVAX QUADRIVALENT is an inactivated vaccine indicated for active immunization for the prevention of influenza disease caused by influenza virus subtypes A and type B contained in the vaccine
- FLUCELVAX Quadrivalent is approved for use in persons 6 Months of age and older
- FLUCELVAX QUADRIVALENT 0.5 mL pre-filled syringes contain no preservative or antibiotics
- FLUCELVAX QUADRIVALENT is standardized according to United States Public Health Service requirements for the 2021 - 2022 influenza season and is formulated to contain a total of 60 micrograms (mcg) hemagglutinin (HA) per 0.5 mL dose in the recommended ratio of 15 mcg HA of each of the following four influenza strains:
- A/Idaho/07/2018 (an A/Brisbane/02/2018 (H1N1)pdm09-like virus), A/Indiana/08/2018 (an A/Kansas/14/2017 (H3N2)-like virus), B/Iowa/06/2017 (a B/Colorado/06/2017-like virus), B/Singapore/INFTT-16-0610/2016 (a B/Phuket/3073/2013-like virus)
|
- AFLURIA QUADRIVALENT is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine
- AFLURIA QUADRIVALENT is approved for use in persons 6 Months and older
- The multi-dose presentation contains thimerosal added as a preservative; each 0.5 mL dose contains 24.5 mcg of mercury
- AFLURIA QUADRIVALENT is standardized according to USPHS requirements for the 2021 - 2022 influenza season and is formulated to contain 60 mcg hemagglutinin (HA) per 0.5 mL dose in the recommended ratio of 15 mcg HA for each of the four influenza strains recommended for the 2020 - 2021 Northern Hemisphere influenza season:
- A/Brisbane/02/2018 (IVR-190) (an A/Brisbane/02/2018 (H1N1)pdm09 – like virus), A/Kansas/14/2017 (X-327) (an A/Kansas/14/2017 (H3N2) – like virus), B/Maryland/15/2016 (a B/Colorado/06/2017 – like virus) and B/Phuket/3073/2013 BVR-1B (a B/Phuket/3073/2013 – like virus). A 0.25 mL dose contains 7.5 mcg HA of each of the same four influenza strains.
|
- Fluad is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza virus subtypes A and type B contained in the vaccine
- FLUAD is approved for use in persons 65 years of age and older
- Each 0.5 mL dose contains at least 15 mcg of hemagglutinin (HA) from each of the following three influenza strains recommended for the 2021 - 2022 influenza season; A/Brisbane/02/2018 IVR-190 (an A/Brisbane/02/2018 (H1N1)pdm09-like virus), A/Kansas/14/2017 X-327 (an A/Kansas/14/2017 (H3N2)-like virus), B/Maryland/15/2016 (a B/Colorado/06/2017-like virus)
- FLUAD also contains MF59C.1 adjuvant (MF59®), a squalene based oil-in-water emulsion
|
